Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

World News

Boehringer to lay off salespeople as Humira biosimilar sales lag

by April 5, 2024
April 5, 2024
Boehringer to lay off salespeople as Humira biosimilar sales lag

Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor US sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.

The German drugmaker said it planned to reduce its customer-facing teams in favor of a hybrid in-person and virtual sales model by June 30, in large part because pharmacy benefit managers (PBMs) had kept branded Humira on their lists of medicines for reimbursement.

That choice has led to less uptake of biosimilar versions of Humira in the United States, including Boehringer’s Cyltezo, it said. The company, which has 53,000 employees worldwide, did not provide details on how many people would be laid off.

Despite nine biosimilars being launched in the U.S. last year, AbbVie has held onto more than 98% of the Humira market.

Boehringer launched Cyltezo last July but has only managed to sell 1,487 prescriptions in total since then, according to IQVIA data. Almost 2.8 million Humira prescriptions have been written during the same period.

Humira until recently was the world’s top selling prescription medicine with annual sales reaching $22 billion in 2022, but has been eclipsed by Merck & Co’s cancer drug Keytruda.

Unlike easy to manufacture pills that can be copied and sold as generics at a huge discount once patents lapse, complex biologic medicines made from living cells cannot be exactly duplicated and so are known as biosimilars. The introduction of biosimilars was supposed to help cut the price of expensive biotech medicines that go off patent, if not by as much as generics.

The German drugmaker priced its branded and unbranded versions the drug at a 5% and 81% discount to Humira’s 2023 list price of $6,922 per month.

Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% discount to Humira.

Boehringer’s Humira biosimilar was the first to be designated interchangeable by the U.S. Food and Drug Administration, meaning it can be substituted for the original without consulting the prescriber.

UnitedHealth Group’s Optum Rx and Cigna’s Express Scripts, two of the largest US PBMs, chose to include Cyltezo on their insurance reimbursement lists last year alongside Humira, Hyrimoz and Amjevita. – Reuters

previous post
US raises commercial and market access issues with China in meeting
next post
Cooperation with South Korea, Philippines important for regional security, says Japan’s Kishida – Reuters News

Related Posts

Biden warns on Beijing’s South China Sea moves...

April 12, 2024

Sheinbaum poised to be Mexico’s 1st female president

June 3, 2024

US has a wrong perception of China, says...

March 7, 2024

Tesla quits Australia auto lobby over claims on...

March 7, 2024

Packaging billionaires to help fund Trump campaign, FT...

March 10, 2024

Gun-shy Australia, reeling from knife crime, weighs public...

April 18, 2024

Sanofi to settle 4,000 Zantac cancer lawsuits in...

April 4, 2024

OPEC+ could delay output hike, sources say

November 29, 2024

Avoid war at all costs – Nguyen

September 6, 2024

Donald Trump joins TikTok and rapidly wins three...

June 3, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • New book exposes Jill Biden’s power grab amid husband’s political demise

      July 8, 2025
    • DeSantis not keen on Musk’s new political party, has another idea for disrupting DC

      July 8, 2025
    • US will ‘have to’ send weapons to Ukraine, Trump says days after Pentagon pause

      July 8, 2025
    • Key advisor called Hunter Biden’s role on strategy call ‘inappropriate’ after he overruled legal guidance

      July 8, 2025
    • Former Biden doctor asks to delay testimony to House committee investigating mental fitness

      July 8, 2025
    • Trump and Netanyahu celebrate ‘historic victory’ against Iran, eye future Middle East peace

      July 8, 2025

    Categories

    • Business (1,296)
    • Politics (6,303)
    • Stocks (904)
    • World News (460)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved